Shifting away from laser photocoagulation for Type 1 ROP, clinicians reported anti-VEGF as the preferred modality of choice over laser for A-ROP and Type 1 ROP in zone 1 and posterior zone 2 [7]. The gene discussed is VEGFA; the disease is retinopathy of prematurity.